PMID- 19852335
OWN - NLM
STAT- MEDLINE
DCOM- 20091116
LR  - 20091026
IS  - 0300-5283 (Print)
IS  - 0300-5283 (Linking)
VI  - 64
IP  - 1
DP  - 2009 Mar
TI  - The A-B-C of haematopoietic stem cell transplantation.
PG  - 94-100; quiz 101
AB  - Haematopoietic stem cell transplantation (HSCT) has progressed rapidly since its 
      introduction about five decades ago. There is now an increasing demand for 
      transplant physicians in both public and private domains to perform this 
      procedure in view of significant improvement of remission rates in haematological 
      malignancies and increasing indications of HSCT. Peripheral blood has largely 
      replaced bone marrow as the preferred source of haematopoietic stem cells (HSC). 
      Transplantation-related mortality and morbidity rates have considerably decreased 
      because of improved conditioning regimens, human leukocyte antigen (HLA) typing 
      methods, supportive care, and most importantly, prophylaxis, diagnosis and 
      treatment of serious infections. New transplantation strategies, such as reduced 
      intensity transplantation, have extended the use of allogeneic transplant to 
      patients with older age and co-morbidities. Current efforts are focused on ways 
      to increase the donor pool and to improve the long term outcome of HSCT survivors 
      in particular to reduce the relapse rate and the late effects of HSCT. This 
      article summarizes the sources and procurement of HSC, the types and process of 
      HSCT, indications for HSCT and complications associated with HSCT with particular 
      reference to the current practice within the local settings.
FAU - Rafeah, N T
AU  - Rafeah NT
AD  - Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan 
      Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.
FAU - Fadilah, S A W
AU  - Fadilah SA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Malaysia
TA  - Med J Malaysia
JT  - The Medical journal of Malaysia
JID - 0361547
SB  - IM
MH  - Graft vs Host Disease/epidemiology
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - Transplantation Conditioning
RF  - 23
EDAT- 2009/10/27 06:00
MHDA- 2009/11/17 06:00
CRDT- 2009/10/27 06:00
PHST- 2009/10/27 06:00 [entrez]
PHST- 2009/10/27 06:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
PST - ppublish
SO  - Med J Malaysia. 2009 Mar;64(1):94-100; quiz 101.